nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.12.2009

Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy

verfasst von: Valentin Fuster, Sarina van der Zee, Marc A. Miller

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Evolving imaging modalities in hypertrophic cardiomyopathy (HCM), such as tissue Doppler, speckle tracking, measures of myocardial blood flow, and cardiac magnetic resonance with gadolinium enhancement, have advanced our understanding of the pathogenesis of myocardial dysfunction in hypertrophic cardiomyopathy. These modalities have the potential to differentiate HCM from other causes of left ventricular hypertrophy when there is uncertainty about the diagnosis and to identify affected individuals in the pre-clinical phase of the disease process. Furthermore, preliminary data suggests that functional imaging techniques may add incremental value to conventional risk stratification tools to identify individuals at high risk for sudden death or progression to congestive heart failure.

Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E. (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation, 92, 785–789.PubMed

Klues, H. G., Schiffers, A., & Maron, B. J. (1995). Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. Journal of the American College of Cardiology, 26, 1699–1708.CrossRefPubMed

Binder, J., Ommen, S. R., Gersh, B. J., et al. (2006). Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: Septal morphological features predict the presence of myofilament mutations. Mayo Clinic Proceedings, 81, 459–467.CrossRefPubMed

Urheim, S., Edvardsen, T., Torp, H., Angelsen, B., & Smiseth, O. A. (2000). Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation, 102, 1158–1164.PubMed

Van de Veire, N. R., De Sutter, J., Bax, J. J., & Roelandt, J. R. (2008). Technological advances in tissue Doppler imaging echocardiography. Heart, 94, 1065–1074.CrossRefPubMed

Efthimiadis, G. K., Giannakoulas, G., Parharidou, D. G., et al. (2006). Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy. American Journal of Cardiology, 98, 1269–1272.CrossRefPubMed

Burns, A. T., McDonald, I. G., Thomas, J. D., Macisaac, A., & Prior, D. (2008). Doin' the twist: New tools for an old concept of myocardial function. Heart, 94, 978–983.CrossRefPubMed

Sun, J. P., Stewart, W. J., Yang, X. S., et al. (2009). Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. American Journal of Cardiology, 103, 411–415.CrossRefPubMed

Bayrak, F., Kahveci, G., Mutlu, B., Sonmez, K., & Degertekin, M. (2008). Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy. European Journal of Echocardiography, 9, 278–283.CrossRefPubMed

10.

Nesbitt, G. C., Mankad, S., & Oh, J. K. (2009). Strain imaging in echocardiography: Methods and clinical applications. International Journal of Cardiovascular Imaging, 25(Suppl 1), 9–22.CrossRefPubMed

11.

Soor, G. S., Luk, A., Ahn, E., et al. (2009). Hypertrophic cardiomyopathy: Current understanding and treatment objectives. Journal of Clinical Pathology, 62, 226–235.CrossRefPubMed

12.

Nagueh, S. F., McFalls, J., Meyer, D., et al. (2003). Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation, 108, 395–398.CrossRefPubMed

13.

Nagueh, S. F., Bachinski, L. L., Meyer, D., et al. (2001). Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation, 104, 128–130.PubMed

14.

Ho, C. Y., Sweitzer, N. K., McDonough, B., et al. (2002). Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation, 105, 2992–2997.CrossRefPubMed

15.

Michels, M., Soliman, O. I., Kofflard, M. J., et al. (2009). Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovascular Imaging, 2, 58–64.CrossRefPubMed

16.

Buakhamsri, A., Popovic, Z. B., Lin, J., et al. (2009). Impact of left ventricular volume/mass ratio on diastolic function. European Heart Journal, 30, 1213–1221.CrossRefPubMed

17.

Richard, P., Charron, P., Carrier, L., et al. (2003). Hypertrophic cardiomyopathy: Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 107, 2227–2232.CrossRefPubMed

18.

Kubo, T., Gimeno, J. R., Bahl, A., et al. (2007). Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. Journal of the American College of Cardiology, 49, 2419–2426.CrossRefPubMed

19.

Du, J., Zhang, C., Liu, J., Sidky, C., & Huang, X. P. (2006). A point mutation (R192H) in the C-terminus of human cardiac troponin I causes diastolic dysfunction in transgenic mice. Archives of Biochemistry and Biophysics, 456, 143–150.CrossRefPubMed

20.

Geske, J. B., Sorajja, P., Nishimura, R. A., & Ommen, S. R. (2007). Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: Correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation, 116, 2702–2708.CrossRefPubMed

21.

Krasnow, N. (1997). Subaortic septal bulge simulates hypertrophic cardiomyopathy by angulation of the septum with age, independent of focal hypertrophy. An echocardiographic study. Journal of the American Society of Echocardiography, 10, 545–555.CrossRefPubMed

22.

Chen-Tournoux, A., Fifer, M. A., Picard, M. H., & Hung, J. (2008). Use of tissue Doppler to distinguish discrete upper ventricular septal hypertrophy from obstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 101, 1498–1503.CrossRefPubMed

23.

Vinereanu, D., Florescu, N., Sculthorpe, N., Tweddel, A. C., Stephens, M. R., & Fraser, A. G. (2001). Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes. American Journal of Cardiology, 88, 53–58.CrossRefPubMed

24.

Shan, K., Bick, R. J., Poindexter, B. J., et al. (2000). Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. Journal of the American College of Cardiology, 36, 891–896.CrossRefPubMed

25.

Yang, H., Sun, J. P., Lever, H. M., et al. (2003). Use of strain imaging in detecting segmental dysfunction in patients with hypertrophic cardiomyopathy. Journal of the American Society of Echocardiography, 16, 233–239.CrossRefPubMed

26.

Nagueh, S. F., Appleton, C. P., Gillebert, T. C., et al. (2009). Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography, 22, 107–133.CrossRefPubMed

27.

van Dalen, B. M., Kauer, F., Soliman, O. I., et al. (2009). Influence of the pattern of hypertrophy on left ventricular twist in hypertrophic cardiomyopathy. Heart, 95, 657–661.CrossRefPubMed

28.

Greenberg, N. L., Firstenberg, M. S., Castro, P. L., et al. (2002). Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility. Circulation, 105, 99–105.CrossRefPubMed

29.

Popovic, Z. B., Kwon, D. H., Mishra, M., et al. (2008). Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. Journal of the American Society of Echocardiography, 21, 1299–1305.CrossRefPubMed

30.

Adabag, A. S., Maron, B. J., Appelbaum, E., et al. (2008). Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Journal of the American College of Cardiology, 51, 1369–1374.CrossRefPubMed

31.

Miller, M. A., Gomes, J. A., & Fuster, V. (2007). Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med, 4, 667–676.CrossRefPubMed

32.

Gorcsan, J., 3 rd, Abraham, T., Agler, D. A., et al. (2008). Echocardiography for cardiac resynchronization therapy: Recommendations for performance and reporting—A report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. Journal of the American Society of Echocardiography, 21, 191–213.CrossRefPubMed

33.

D'Andrea, A., Caso, P., Severino, S., et al. (2006). Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. European Heart Journal, 27, 1311–1318.CrossRefPubMed

34.

Maron, B. J., Olivotto, I., Spirito, P., et al. (2000). Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation, 102, 858–864.PubMed

35.

D'Andrea, A., Caso, P., Severino, S., et al. (2005). Association between intraventricular myocardial systolic dyssynchrony and ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Echocardiography, 22, 571–578.CrossRefPubMed

36.

Nagakura, T., Takeuchi, M., Yoshitani, H., et al. (2007). Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy. Echocardiography, 24, 677–684.CrossRefPubMed

37.

Kato, T. S., Izawa, H., Komamura, K., et al. (2008). Heterogeneity of regional systolic function detected by tissue Doppler imaging is linked to impaired global left ventricular relaxation in hypertrophic cardiomyopathy. Heart, 94, 1302–1306.CrossRefPubMed

38.

Cleland, J. G., Daubert, J. C., Erdmann, E., et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352, 1539–1549.CrossRefPubMed

39.

Sanderson, J. E. (2009). Echocardiography for cardiac resynchronization therapy selection: fatally flawed or misjudged? Journal of the American College of Cardiology, 53, 1960–1964.CrossRefPubMed

40.

Maron, M. S., Olivotto, I., Maron, B. J., et al. (2009). The case for myocardial ischemia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 54, 866–875.CrossRefPubMed

41.

Maron, B. J., Wolfson, J. K., Epstein, S. E., & Roberts, W. C. (1986). Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 8, 545–557.PubMed

42.

Basso, C., Thiene, G., Corrado, D., Buja, G., Melacini, P., & Nava, A. (2000). Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Human Pathology, 31, 988–998.CrossRefPubMed

43.

Cecchi, F., Olivotto, I., Gistri, R., Lorenzoni, R., Chiriatti, G., & Camici, P. G. (2003). Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. New England Journal of Medicine, 349, 1027–1035.CrossRefPubMed

44.

Pitcher, D., Wainwright, R., Maisey, M., Curry, P., & Sowton, E. (1980). Assessment of chest pain in hypertrophic cardiomyopathy using exercise thallium-201 myocardial scintigraphy. British Heart Journal, 44, 650–656.CrossRefPubMed

45.

Camici, P. G., & Crea, F. (2007). Coronary microvascular dysfunction. New England Journal of Medicine, 356, 830–840.CrossRefPubMed

46.

Cannon, R. O., 3 rd, Dilsizian, V., O'Gara, P. T., et al. (1991). Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation, 83, 1660–1667.PubMed

47.

Grover-McKay, M., Schwaiger, M., Krivokapich, J., Perloff, J. K., Phelps, M. E., & Schelbert, H. R. (1989). Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 13, 317–324.PubMed

48.

Choudhury, L., Rosen, S. D., Patel, D., Nihoyannopoulos, P., & Camici, P. G. (1997). Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography. European Heart Journal, 18, 108–116.PubMed

49.

Kawada, N., Sakuma, H., Yamakado, T., et al. (1999). Hypertrophic cardiomyopathy: MR measurement of coronary blood flow and vasodilator flow reserve in patients and healthy subjects. Radiology, 211, 129–135.PubMed

50.

Radvan, J., Choudhury, L., Sheridan, D. J., & Camici, P. G. (1997). Comparison of coronary vasodilator reserve in elite rowing athletes versus hypertrophic cardiomyopathy. American Journal of Cardiology, 80, 1621–1623.CrossRefPubMed

51.

Sharma, S., Elliott, P. M., Whyte, G., et al. (2000). Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. Journal of the American College of Cardiology, 36, 864–870.CrossRefPubMed

52.

Sardanelli, F., Molinari, G., Petillo, A., et al. (1993). MRI in hypertrophic cardiomyopathy: A morphofunctional study. Journal of Computer Assisted Tomography, 17, 862–872.CrossRefPubMed

53.

Rickers, C., Wilke, N. M., Jerosch-Herold, M., et al. (2005). Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation, 112, 855–861.CrossRefPubMed

54.

Moon, J. C., Fisher, N. G., McKenna, W. J., & Pennell, D. J. (2004). Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart, 90, 645–649.CrossRefPubMed

55.

Zerhouni, E. A., Parish, D. M., Rogers, W. J., Yang, A., & Shapiro, E. P. (1988). Human heart: Tagging with MR imaging—A method for noninvasive assessment of myocardial motion. Radiology, 169, 59–63.PubMed

56.

Kuribayashi, T., & Roberts, W. C. (1992). Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. American Journal of Cardiology, 70, 1333–1340.CrossRefPubMed

57.

Heng, M. K., Janz, R. F., & Jobin, J. (1985). Estimation of regional stress in the left ventricular septum and free wall: An echocardiographic study suggesting a mechanism for asymmetric septal hypertrophy. American Heart Journal, 110, 84–90.CrossRefPubMed

58.

Lima, J. A., Judd, R. M., Bazille, A., Schulman, S. P., Atalar, E., & Zerhouni, E. A. (1995). Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation, 92, 1117–1125.PubMed

59.

Wu, E., Judd, R. M., Vargas, J. D., Klocke, F. J., Bonow, R. O., & Kim, R. J. (2001). Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet, 357, 21–28.CrossRefPubMed

60.

Roldan, V., Marin, F., Gimeno, J. R., et al. (2008). Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. American Heart Journal, 156, 85–91.CrossRefPubMed

61.

Esposito, A., De Cobelli, F., Perseghin, G., et al. (2009). Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging. Heart, 95, 228–233.CrossRefPubMed

62.

Choudhury, L., Mahrholdt, H., Wagner, A., et al. (2002). Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 40, 2156–2164.CrossRefPubMed

63.

Debl, K., Djavidani, B., Buchner, S., et al. (2006). Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: Visualisation of focal fibrosis. Heart, 92, 1447–1451.CrossRefPubMed

64.

Suk, T., Edwards, C., Hart, H., & Christiansen, J. P. (2008). Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ, 17, 370–374.CrossRefPubMed

65.

Jung, W. I., Sieverding, L., Breuer, J., et al. (2000). 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation, 101(12), E121. PMID: 9657474.

66.

de Roos A., Doornbos, J., Luyten, P. R., Oosterwaal, L. J., van der Wall, E. E., & den Hollander, J. (1992). Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. Journal of Magnetic Resonance Imaging, 2(6), 711-9. PMID: 1446116.

67.

Blackledge, M. J., Rajagopalan, B., Oberhaensli, R. D., Bolas, N. M., Styles, P., & Radda, G. K. (1987). Quantitative studies of human cardiac metabolism by 31P rotating-frame NMR. Proceedings of the National Academy of Sciences of the United States of America, 84, 4283–4287.CrossRefPubMed

68.

Neubauer, S., Horn, M., Cramer, M., et al. (1997). Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation, 96, 2190–2196.PubMed

69.

Shivu, G. N., Abozguia, K., Phan, T. T., Ahmed, I., Henning, A., & Frenneaux, M. (2008). (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T. European Journal of Radiology, Dec. 2 [Epub ahead of print].

70.

Sieverding, L., Jung, W. I., Breuer, J., et al. (1997). Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. American Journal of Cardiology, 80, 34A–40A.CrossRefPubMed

71.

Thet Thet, L., Takeda, T., Wu, J., et al. (2003). Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: Quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI. European Journal of Nuclear Medicine and Molecular Imaging, 30, 966–973.CrossRef

72.

Lefroy, D. C., de Silva, R., Choudhury, L., et al. (1993). Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography. Journal of the American College of Cardiology, 22, 1653–1660.PubMedCrossRef

Titel: Evolving Anatomic, Functional, and Molecular Imaging in the Early Detection and Prognosis of Hypertrophic Cardiomyopathy
verfasst von: Valentin Fuster
Sarina van der Zee
Marc A. Miller
Publikationsdatum: 01.12.2009
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2009
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-009-9133-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?

Role of Animal Models in HCM Research

Genetic Counseling and Testing for Hypertrophic Cardiomyopathy: the Pediatric Perspective

Experimental Therapies in Hypertrophic Cardiomyopathy